Table 2.

Baseline characteristics in the two groups

Control Group (n = 56)Allopurinol Group (n = 57)
Renal pathology, % (n)
    Diabetes mellitus18 (10)16 (9)
    Vascular nephropathy45 (25)49 (28)
    Glomerulonephritis9 (5)2 (1)
    Polycystic kidney disease2 (1)3 (2)
    Interstitial nephropathy3 (2)14 (8)
    Systemic vasculitis3 (2)0 (0)
    Unknown etiology renal disease20 (11)16 (9)
Diabetes mellitus, % (n)36 (20)39 (22)
Ischemic cardiopathy, % (n)18 (10)29 (16)
Cerebrovascular disease, % (n)2 (2)9 (2)
Periferic vascular disease, % (n)4 (1)4 (5)
Diuretics use, % (n)54 (30)63 (36)
    Thiazide diuretics, n1315
    Loop diuretics, n1721
RAAS blockers, % (n)75 (41)85 (47)
Calcium-channel blockers, % (n)36 (20)23 (13)
Statins treatment, % (n)44 (24)49 (27)
Antiplatelet treatment, % (n)33 (18)27 (15)
Double treatment, % (n)50 (28)56 (32)
Triple treatment, % (n)20 (11)14 (8)
  • No significant differences were observed between the different analyzed variables.

  • Double treatment, RAAS blockers and statins or antiplatelet treatment.

  • Triple treatment, RAAS blockers and statins and antiplatelet treatment.